Aug 4, 2026 06:00AM
Jun 1, 2026 11:00AM
Jun 1, 2026 11:00AM
May 14, 2026 09:15AM
May 5, 2026 06:00AM
Apr 30, 2026 06:01AM
Apr 30, 2026 06:00AM IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
Apr 13, 2026 01:29PM
Apr 13, 2026 06:00AM
Apr 13, 2026 06:00AM
Mar 23, 2026 04:56AM
Feb 17, 2026 06:00AM
Feb 6, 2026 04:45AM
Jan 11, 2026 12:00PM IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
Dec 11, 2025 06:00AM
Dec 11, 2025 06:00AM
Dec 10, 2025 06:01AM
Dec 10, 2025 06:00AM
Dec 4, 2025 07:00PM
Dec 1, 2025 06:00AM
Dec 1, 2025 06:00AM IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
Nov 4, 2025 06:00AM
Oct 20, 2025 06:30AM
Oct 20, 2025 06:30AM
Oct 7, 2025 07:53AM
Sep 11, 2025 08:18AM
Sep 8, 2025 08:00AM
Sep 8, 2025 08:00AM IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
Sep 3, 2025 06:00AM
Sep 3, 2025 06:00AM
Sep 2, 2025 06:01AM
Sep 2, 2025 06:00AM
Aug 5, 2025 06:00AM
Jul 24, 2025 09:25AM
Jul 24, 2025 09:25AM IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
May 6, 2025 06:05AM
May 6, 2025 06:01AM
May 6, 2025 06:00AM
Apr 14, 2025 06:00AM
Apr 14, 2025 06:00AM
Mar 31, 2025 06:29AM
Mar 31, 2025 06:00AM IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
Feb 13, 2025 06:05AM
Jan 2, 2025 04:00PM
Dec 21, 2024 10:00AM
Dec 17, 2024 06:00AM
Dec 16, 2024 06:04AM
Dec 16, 2024 06:00AM
Dec 10, 2024 06:01AM IDEAYA (IDYA) Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA®
Dec 10, 2024 06:00AM

327,801 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All